|
| 말기 신부전증 환자에서의 B형 간염바이러스 감염 |
| 김태준 , 조성원 , 이희발 |
|
|
| Abstract |
|
The prevalence of hepa.it is B virus (HBV) in- fection in patients with endstage renal disease (ESRD) before and during hemodialysis (HD) and/or continuous ambulatory peritoneal dialysis (CAPD) was evaluated in 82 patients with ESRD. HBV markers (HBsAg, HBeAg, anti-HBc and anti- HBs) were obtained by RIA shortly hefore or within 3 months of either HD or CAPD in all 82 patients and were repeated in 49 patients in a mean period of 10.6 months on HD (8 patients) or in 10, 8 months on CAPD (41 patients).Eight patients (9. 8%) had HBsAg and 3g patients (47. 6%) anti-HBs on the initial examination. Twenty-four (30. 8%) of 78 patients in whom all 4 makers were obtained had none of the markers. HBV markers were also obtained in 242 control patients with no known renal or liver diseaae and HBsAg was detected in17 patients (7. 0%) and anti-HBs in 116 patients (47. 9%). There was no statistically significant difference in the prevalence of HBsAg and anti-HBs between ESRD and control patients. HBV markers remained unchanged in 4 patients during HD and in 31 patients while on CAPD. Persistent HBs antigenemia was ob erved in 1 of 1 patient on HD and 2 of 4 on CAPD. HBsAgand/or HBeAg appeared in 2 of 7 patients on HD and in none of 37 patients during CAPD. Anti- HBs appeared in none of 6 patients on HD but in 2 of 17 patients during CAPD. The results of this study suggest that the prev- alence of HBV infection in ESRD patients is not significantly different from control population and that HB antigenemia may occur less frequently among CAPD patients as compared to HD patients. The significance of these findings needs to he confirmed, however, in the future studies involving larger population during a longer follow-up period. |
|
PDF Links
Download Citation
